In this series, we will be introducing one-by-one the new members that have joined our ecosystem in the last six months. Follow us for a new article next week!
We are proud to present one of the latest additions to our cluster – Hubro Therapeutics.
Hubro Therapeutics is a Norwegian biotech start-up from 2018 that develops immunotherapies against cancer. These treatments aim to trigger the body’s immune system to fight cancer. The company is currently situated in Oslo Cancer Cluster Incubator, where they are using the laboratory facilities to develop their treatments.
We talked with Jon Amund Eriksen, founder and CEO of Hubro Therapeutics, to find out a little bit more about the company, their work in cancer research and the reason why they joined Oslo Cancer Cluster.
Could you briefly describe Hubro Therapeutics and the role you take in cancer?
“Hubro Therapeutics AS is a biotech company based on thirty years of R&D experience in the field of immunotherapy of cancer. The company is specialising in developing peptide vaccines targeting shared cancer specific neo-antigens, focusing on design and development of novel peptides and peptide compositions for targeting frameshift mutations in micro-satellite instable (msi) cancers. The lead candidate vaccine targeting frameshift mutation in TGFbR2 is currently in development for clinical testing in msi-colorectal cancer and potentially msi-gastric cancer,” said Jon Amund Eriksen, founder and CEO.
Why did you join Oslo Cancer Cluster?
“For us, Oslo Cancer Cluster with its incubator and laboratory facilities provides a perfect opportunity to operate in a highly relevant and focused scientific environment as well as to generate our own experimental results without heavy investments,” said Jon Amund Eriksen, founder and CEO.
This article was originally published in Norwegian on Altomdinhelse.no by Mediaplanet, and was written by Jónas Einarsson, CEO of Radforsk and initiator of Oslo Cancer Cluster, Oslo Cancer Cluster Incubator and Oslo Cancer Cluster Innovation Park.
We wish to expand Oslo Cancer Cluster Innovation Park with close to 50 000 square metres the next five to seven years. The goal is to develop even better cancer treatments to improve the lives of cancer patients, in close collaboration with the ecosystem around the park.
On 24 August 2015, the Norwegian Prime Minister Erna Solberg opened Oslo Cancer Cluster Innovation Park. In her speech, she said: “Oslo Cancer Cluster Innovation Park will fulfil an important role in the development of the cancer treatments of the future.”
That moment was the starting point for a unique collaboration between cancer researchers, clinicians, teachers, students, business developers and numerous other professions that are needed to develop tomorrow’s cancer treatments.
Ullern Upper Secondary School is one of the most sought-after schools in Oslo and the number of students is ever increasing. The students are offered the opportunity to participate in the school collaboration with Oslo Cancer Cluster, to educate the researchers and entrepreneurs of tomorrow. In the autumn of 2019, the researcher programme was initiated at Ullern, which is a unique opportunity for students in Oslo to specialise in biomedical subjects.
Many developments planned
Everything mentioned above is only what is happening inside the Innovation Park. In the nearby area, there are many unique developments that will change the treatment of cancer patients in coming years:
The Institute for Cancer Research is being developed further under the proficient management of Professor Kjetil Taskén. The talented researchers at the Institute are delivering internationally renowned research every day.
Oslo University Hospital is the only hospital in Scandinavia accredited as a “Comprehensive Cancer Center”. The accreditation demands constant development of research, infrastructure and treatments.
Still a way to go
Things are still far from perfect. Almost everyday in the news, there are discussions about whether Norwegian cancer patients are offered the best cancer treatments. I believe we still have a way to go. In order to give better cancer treatments, we must heavily invest in the development of:
Cell and gene therapy
The treatment of antibiotic resistance
Because of the success we have had so far with the Oslo Cancer Cluster Innovation Park and the need to strengthen cancer care further, we wish to expand the Oslo Cancer Cluster Innovation Park during the next five to seven years with close to 50 000 square metres. The first expansion will total 7 000 square metres. The planning scheme begins this year and the building itself will be located between the Innovation Park and the Institute for Cancer Research.
The expansion of the Innovation Park is an important supplement to the plans on developing Oslo into Oslo Science City. We are also a living example of how public-private partnerships is the way to go in order to build a sustainable health industry, like the White Paper on the Health Industry has stated.
Norwegian cancer research is world class. The 15 companies in the Radforsk portfolio has spun out of this research. We have enormous ambitions to contribute even more to the development of the cancer treatments of tomorrow – to improve the lives of cancer patients all over the world.
As Prime Minister Erna Solberg said in her speech on 24 August 2015: “Smart minds and new ideas, students and professors, Norwegians and foreigners, founders and employees. Together for a common goal: to improve the treatment of the approximately 30 000 Norwegians that are diagnosed with cancer every year.”
That statement is still true today.
Oslo Cancer Cluster Innovasjonspark:
Kraftsenter for utvikling av kreftbehandling
Vi ønsker å utvide Oslo Cancer Cluster Innovasjonspark med nærmere 50.000 km² de neste fem til syv årene. Målet er å utvikle enda bedre kreftbehandling til det beste for kreftpasienter, i tett samarbeid med økosystemet rundt parken.
Av Jónas Einarsson, administrerende direktør i Radforsk og initiativtaker til Oslo Cancer Cluster, Oslo Cancer Cluster Inkubator og Oslo Cancer Cluster Innovasjonspark.
Den 24. august 2015 åpnet Statsminister Erna Solberg Oslo Cancer Cluster Innovasjonspark. I sin tale sa hun: «Oslo Cancer Cluster Innovasjonspark vil fylle en viktig rolle i utforming av fremtidens kreftbehandling.»
Og med det gikk startskuddet gikk for et unikt samarbeid mellom kreftforskere, klinikere, lærere, elever, forretningsutviklere og en rekke andre profesjoner som trengs for å utvikle morgendagens kreftbehandling.
Felles for alle oss som jobber her, er at vi har én visjon: Oslo Cancer Cluster Innovasjonspark og miljøet rundt med Radiumhospitalet og Institutt for Kreftforskning, skal være et internasjonalt kraftsenter for utvikling av kreftbehandling.
Fem år etter åpningen så lever vi ut denne visjonen hver dag. Jeg vil tørre å påstå at det vi har bidratt til er en suksess:
Oslo Cancer Cluster Incubator huser i dag ni oppstartsbedrifter, og vi jobber tett med syv andre som sitter andre steder og som det ikke er plass til
Ullern videregående skole er en av de best søkte skolene i Oslo, og øker stadig elevtallet. Elevene på skolen får tilbud om å delta i det skolefaglige samarbeidet med Oslo Cancer Cluster, for å utdanne morgendagens forskere og entreprenører. Høsten 2019 startet Forskerlinja, et unikt tilbud til skoleelever i Oslo om fordypning i biomedisinske fag
Dette er bare inne i Innovasjonsparken. I området rundt oss skjer det unike ting som endrer måten pasienter med kreft blir behandlet på om få år:
I 2023 åpner det nye klinikkbygget på Radiumhospitalet med et spesialisert protonsenter
Institutt for Kreftforskning blir stadig videreutviklet under kyndig ledelse av professor Kjetil Taskén. De dyktige forskerne ved instituttet leverer daglig internasjonalt, anerkjent forskning
Oslo universitetssykehus er som eneste sykehus i Skandinavia akkreditert som et «Komplett kreftsenter», «Comprehensive Cancer Center». Akkrediteringen krever konstant utvikling av forskning, infrastruktur og behandling
Likevel er ikke tingenes tilstand rosenrød. I media kan vi nesten daglig lese diskusjoner om hvorvidt kreftbehandlingen pasienter i Norge tilbys er den beste. Min påstand er at vi har mye å gå på. For å gi bedre kreftbehandling må vi satse tungt på å utvikle:
Celle- og genterapi
Behandling av antibiotikaresistens
På bakgrunn av den suksessen vi har hatt med Oslo Cancer Cluster Innovasjonspark så langt, og behovet for å styrke kreftomsorgen ytterligere, ønsker vi de neste fem til syv årene å utvide Oslo Innovasjonsparken med nær 50.000 km². Den første utvidelsen vil være på 7000 km². Prosjekteringen starter i år, og selve bygget vil ligge mellom Innovasjonsparken og Institutt for Kreftforskning.
Utvidelsen av Innovasjonsparken er et viktig tilskudd til planene om å utvikle Oslo som en kunnskapshovedstad, Oslo Science City. Vi er i tillegg et levende eksempel på at privat-offentlig samarbeid er veien å gå for å bygge en bærekraftig helsenæring, slik Stortingsmeldingen om helsenæring slår fast.
Norsk kreftforskning er i verdensklasse. Våre 15 bedrifter i Radforsk-porteføljen er spunnet ut av denne forskningen. Vi har enorme ambisjoner om at vi kan bidra enda mer til utviklingen av morgendagens kreftbehandling – til det beste for kreftpasienter over hele verden.
Som Statsminister Erna Solberg sa i sin tale den 24. august 2015: «Kloke hoder og nye ideer, studenter og professorer, nordmenn og utlendinger, gründere og ansatte. Samlet med ett felles mål: å bedre behandlingen til de om lag 30.000 nordmenn som blir diagnostisert med kreft hvert år.»
Engaging presentations by leading international and Norwegian oncology experts at the 12th Cancer Crosslinks “Progress in Cancer Care – A tsunami of promises or Game Changing Strategies?”.
Oslo Cancer Cluster’s annual meeting gathered more than 350 delegates from all over Norway at the Oslo Cancer Cluster Innovation Park, and more than 50 participants followed the live stream. The record high participation shows the large interest in translational cancer research and the importance of the programme for the Norwegian oncology community.
Cancer Crosslinks has become one of the largest national meeting places for oncologists, haematologists, translational researchers, regulatory experts and industry representatives. The meeting offers a full day educational program.
The aim of the conference is to stimulate broader interactions between researchers and clinicians, to encourage translational and clinical research, and to inspire collaborations. Novel partnerships between industry, academia and authorities are essential to deliver new treatments and diagnostics to Norwegian cancer patients.
“At the start of 2020, cancer patients have more treatment options than ever before. Immuno-oncology is firmly established as the fourth pillar of cancer treatment and the tremendous progress in the field is reflected in increased survival rates,” said Jutta Heix, Head of International Affairs, Oslo Cancer Cluster. “However, many patients do not benefit from novel treatments and we still have significant gaps in our understanding of the complex biological mechanisms. Deciphering this complexity is a task for the decade to come. The Cancer Crosslinks 2020 speakers are shedding light on emerging concepts and key challenges and discuss how they are addressing them to advance cancer care.”
The audience at Cancer Crosslinks 2020. Photo: Cameo Productions UB/Oslo Cancer Cluster
An inspiring programme
Referring to a record number of new oncology drug approvals in recent years and an enormous global pipeline of drugs in late-stage development, this year’s programme addressed the question “Progress in Cancer Care – A Tsunami of Promises or Game-Changing Strategies?”. Distinguished international experts from leading centres in the US and Europe presented emerging concepts, recent progress and key questions to be addressed for both solid and haematological cancers.
Cancer researchers and clinicians from all of Norway enjoyed excellent presentations and engaging discussions with speakers and colleagues.
“Cancer Crosslinks 2020 gave me an opportunity to listen to talks by international top scientists, and discuss some of the latest developments in translational cancer research with meeting participants from academia and industry in a relaxed and inspiring setting,” said Johanna Olweus, Head of Department of Cancer Immunology at the Institute for Cancer Research.
“Cancer Crosslinks is always a meeting that makes me proud of being part of Oslo Cancer Cluster. It is inspiring to see Norwegian and international participants come together to discuss recent progress in cancer research and how to develop cancer treatments for the patients,” said Øyvind Kongstun Arnesen, Chairman of the Board, Oslo Cancer Cluster.
The day programme was complemented with an evening reception in the city center where speakers and delegates continued their lively discussions and listened to an inspiring talk by Ole Petter Ottersen, President of Karolinska Institute, at Hotel Continental in Oslo.
Cancer Crosslinks was established by Oslo Cancer Cluster in 2009 in collaboration with the pharmaceutical company Bristol-Myers Squibb.
“Cancer Crosslinks 2020 has been a fantastic conference, where the presenters have given an excellent description of current and near future achievements within cancer research and the importance of understanding the underlying biology of cancer to rationally give patients the correct cancer therapy. In particular within immunotherapy, there is a need to understand the dynamic complexity of tumor immunology and how to apply the best and tailored immuno-oncology based treatment strategy for cancer patients,” said Ali Areffard, Disease Area Specialist Immuno-Oncology, Bristol-Myers Squibb.
This year, the pharmaceutical company Sanofi Genzyme Norway was a proud co-sponsor of the meeting.
“It was great to be able to provide a platform for interaction between the Norwegian scientific cancer environment and top international research capacities. Therefore, it was with huge enthusiasm Sanofi Genzyme co-sponsored this important conference. New treatment options in oncology are developing fast, where new treatment modalities provide clinicians with additional and superior options. New treatments specifically targeting the malignant cells, as well as activating the host immune response towards the cancer, provides tools to significantly improve current cancer treatments. This year’s Cancer Crosslinks conference gave an excellent insight into this,” said Knut Steffensen, Medical Advisor Hematology Nordic & Baltics, Sanofi Genzyme.
Interview with Prof. Jason Luke
View the interview with Prof. Jason Luke, by HealthTalk, in the video below:
Interview with Prof. Michel Sadelain
View the interview with Prof. Michel Sadelain, by HealthTalk, in the video below:
The speakers at Cancer Crosslinks 2020
Jason J. Luke, MD, FACP, Director of the Cancer Immunotherapeutics Center, Associate Professor of Medicine, University of Pittsburgh Medical Center and Hillman Cancer Center, USA. Photo: Cameo UB Productions/Oslo Cancer Cluster
Stefani Spranger, Howard S. and Linda B. Stern Career Development Assistant Professor, Koch Institute for Integrative Cancer Research at MIT, Cambridge, USA. Photo: Cameo UB Productions/Oslo Cancer Cluster
Harriet Wikman, Professor, Group Leader, Center for Experimental Medicine, Institute of Tumor Biology, University Medical Centre Hamburg-Eppendorf, Germany. Photo: Cameo UB Productions/Oslo Cancer Cluster
Vessela Kristensen, Head of Research and Development and Director of Research at the Dept. of Medical Genetics, Oslo University Hospital, Norway. Photo: Cameo UB Productions/Oslo Cancer Cluster
Peter A. Fasching, Professor of Translational Gynecology and Obstetrics, University Hospital and Comprehensive Cancer Center Erlangen-EMN, Germany. Photo: Cameo UB Productions/Oslo Cancer Cluster
Karl Johan Malmberg, Professor, Group Leader Dept. of Cancer Immunology and Director STRAT-CELL, Oslo University Hospital, Norway. Photo: Cameo UB Productions/Oslo Cancer Cluster
Michel Sadelain, MD, PhD, Professor, Director, Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, USA. Photo: Cameo UB Productions/Oslo Cancer Cluster
Bjørn Tore Gjertsen, Professor of Hematology, Centre for Cancer Biomarkers CCBIO, Dept. of Clinical Science, University of Bergen, Norway. Photo: Cameo UB Productions/Oslo Cancer Cluster
Hermann Einsele, Professor, Chair, Dept. of Internal Medicine II, Head of the Clinical and Translational Research Program on Multiple Myeloma, University Hospital Wuerzburg, Germany. Photo: Cameo UB Productions/Oslo Cancer Cluster
We want to accelerate cancer research in T cell immunotherapy!
In order to promote research collaboration, spread knowledge and exchange ideas, Oslo Cancer Cluster arranged a seminar together with Nature Research this week. The topic was T Cell Immunotherapy: Advances, Challenges and Future Directions.
What is T cell immunotherapy?
T cell immunotherapy is a rapidly growing area of research in cancer treatment. The research focuses on finding new ways to trigger the immune system to kill cancer cells.
The treatment method involves collecting T cells (a type of immune system cell) from a patient’s blood sample. The T cells are then modified in the laboratory so they will bind to cancer cells and destroy them.
One way to do this is called CAR T therapy. This involves adding a gene for a special receptor that binds to a specific protein (also called an antigen) on the patient’s cancer cells. The special receptor is called a chimeric antigen receptor (CAR). These cells are grown in large numbers in the laboratory and then infused in the patient to create an immune response.
Many researchers attended the Nature Café for the opportunity to learn more about recent advances in T cell immunotherapy. Photo: Christian Tandberg
Why is cell therapy important?
Research into T cell immunotherapy is important, because it has the potential to treat and cure cancer. T cell immunotherapy can help cancer patients live longer and potentially has fewer side effects than traditional treatment methods, such as chemotherapy, radiation therapy and surgery.
However, more research is needed to make T cell immunotherapy work on all kinds of cancer. For example, some patients with haematologic cancer, cancers that develop in the blood-forming tissue, relapse into disease after treatment. Moreover, T cell immunotherapy does not work on all patients with solid cancer tumours yet.
Researchers wish to know why some cancers are resistant to T cell immunotherapy and why some patients acquire resistance to the treatment over time. Some patients also experience toxic side effects to T cell immunotherapy. Moreover, researchers are continually searching for possible new antigens (proteins) to target.
There are still many unanswered questions and that is why we need to accelerate the research.
Members of the audience were eager to find out more about this rapidly growing area of research. Photo: Christian Tandberg
Why did we arrange this event?
The Norwegian research environment in cancer immunotherapy is world-class. But Norway is a small country and researchers need access to international partners and expertise to develop their findings.
The purpose of the event was to highlight recent findings in T cell immunotherapy. There was also the opportunity to discuss ongoing challenges and opportunities in the development of these types of treatments.
Among the guests were several prominent Norwegian cancer researchers, the pharma industry, hospital clinicians, biotech start-ups, and more. During the seminar, many of the participants in the audience asked follow-up questions and the café breaks were buzzing with conversations between researchers.
The event was an opportunity to discuss with and learn from prominent researchers in the cell therapy field. Photo: Christian Tandberg
Watch the video below to see a few of the participants’ reactions:
Meet the speakers
The moderator for the event was Saheli Sadanand, Associate Editor, Research Manuscripts at Nature Medicine. Photo: Christian Tandberg
The first speaker was Sara Ghorashian from the University College London. Dr. Ghorashian is a consultant Paediatric Haematologist at Great Ormond Street Hospital for Children in London, and the co-investigator or lead UK investigator for six different CAR T cell clinical trials. She talked about her research to improve outcomes of CAR T cell therapy in patients with acute lymphoblastic leukemia. This is a type of cancer in the blood. Photo: Christian Tandberg
The second speaker was Attilio Bondanza, who is a physician-scientist and the CAR T cell program leader at Novartis Institutes of Biomedical Research in Basel, Switzerland. Before joining Novartis, Dr. Bondanza was a professor at the San Raffeale University Hospital, where he led the Innovative Immunotherapies Unit. Dr. Bondanza talked about his work to model CAR T cell efficacy and CAR T cell-induced toxicities pre-clinically. Photo: Christian Tandberg
The third speaker was Sara Mastaglio, who is a physician scientist specialising in haematology at San Raffaele Scientific Institute, in Milan. She has been actively involved in the development and clinical application of CAR T cell therapies. Dr. Mastaglio discussed her research on genome-edited T cells for the treatment of haematological malignancies. Photo: Christian Tandberg
The last speaker was Aude Chapuis, who is an assistant member of the Fred Hutchinson Cancer Research Center in Seattle. In addition to running a lab, she sees patients as an attending physician at the Fred Hutch Bone Marrow Transplant Program at the Seattle Cancer Care Alliance. Dr. Chapuis discussed mechanisms of response and resistance to instruct next generations of T cell receptor gene therapy. Photo: Christian Tandberg
Want to find out more?
In February 2020, the journal Nature Research will publish an article with a more detailed overview of the speakers, their presentations and the research. We will provide a link here when it is available!
If you enjoyed this event, please subscribe to our newsletter to receive invitations to our upcoming events and a digest of our latest news.
We want to thank our sponsors for helping us make this event happen.
Oslo Cancer Cluster is an oncology research and industry cluster dedicated to improving the lives of cancer patients by accelerating the development of new cancer diagnostics and medicines.
We are a national non-profit member organization with about 90 members. Our members are Norwegian and international companies, research and financial institutions, university hospitals and organizations – all working in the cancer field.